Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Dose and Single Subcutaneous Dose of BI 655130 in Healthy Japanese Male Volunteers (Double-blind, Randomised, Placebo-controlled Design).
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
At a glance
- Drugs BI 655130 (Primary) ; BI 655130 (Primary)
- Indications Palmoplantar pustulosis; Pustular psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Planned End Date changed from 16 Dec 2017 to 5 Jan 2018.
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.